Male breast carcinoma: increased awareness needed

Male breast carcinoma is a rare condition. Few male breast cancer-specific epidemiological or clinical trial data are available - our understanding of male breast cancer thus comes from studies of female breast cancer, painting an inaccurate picture when it comes to determining contributing factors....

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research : BCR 2011-09, Vol.13 (5), p.219-219, Article 219
Main Authors: White, Jonathan, Kearins, Olive, Dodwell, David, Horgan, Kieran, Hanby, Andrew M, Speirs, Valerie
Format: Article
Language:English
Subjects:
Australia - epidemiology
BRCA2 Protein - genetics
Breast cancer
Breast Neoplasms, Male - epidemiology
Breast Neoplasms, Male - etiology
Breast Neoplasms, Male - therapy
Canada - epidemiology
Cancer research
Carcinoma
England - epidemiology
Epidemiology
Health Knowledge, Attitudes, Practice
Humans
Life Style
Male
Prolactin
Review
Risk Factors
Scotland - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Male breast carcinoma is a rare condition. Few male breast cancer-specific epidemiological or clinical trial data are available - our understanding of male breast cancer thus comes from studies of female breast cancer, painting an inaccurate picture when it comes to determining contributing factors. Clinicians report an increase in diagnoses of male breast cancer but this has not been formally reported. We therefore undertook a review of data obtained from four western nations: England, Scotland, Canada and Australia. When adjusted for age, this review clearly showed an increase in the incidence of male breast cancer over a 15-year period. Reasons for the increased incidence are discussed in the context of suggested risk factors such as BRCA2 and lifestyle changes over the past few decades. The clinical management of male breast carcinoma is considered, in particular the potential role of aromatase inhibitors and fulvestrant and targeting pathways involving prolactin and androgen receptor.
ISSN:1465-542X
1465-5411
1465-542X
DOI:10.1186/bcr2930